On Friday, Shares of Mattel, Inc. (NASDAQ:MAT), gained 1.17% to $27.15.
Mattel, declared the appointment of Joseph B. Johnson as Senior Vice President and Corporate Controller, effective right away.
Mr. Johnson, age 52, joins Mattel from Chiquita Brands International, Inc., a leading global marketer and distributor of food products, where he served as Vice President, Chief Accounting Officer & Treasurer. Formerly, Mr. Johnson held a number of leadership roles with Resolute Forest Products, an international wood and paper products company, counting Senior Vice President, Finance and Chief Accounting Officer, Vice President and Corporate Controller and Director of Financial Reporting. Earlier in his career, Mr. Johnson spent nearly 14 years at Ernst & Young LLP. A certified public accountant, Mr. Johnson holds a bachelor’s degree in business administration with an emphasis in accounting from the University of North Florida.
Mr. Johnson succeeds Scott Topham, who has elected to retire from Mattel.
Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl.
Shares of The WhiteWave Foods Company (NYSE:WWAV), inclined 5.44% to $46.10, during its last trading session, hitting its highest level.
The WhiteWave Foods Company, stated record results for the first quarter ended March 31, 2015.
WhiteWave stated first quarter 2015 adjusted diluted earnings per share of $0.24, not taking into account operating investments associated with its China joint venture. Counting joint venture investments, WhiteWave stated first quarter 2015 adjusted diluted earnings per share of $0.22.
Net sales for first quarter 2015 were $911 million, a 10 percent enhance from net sales of $830 million in first quarter 2014. These results were driven by strong growth across the Americas Foods & Beverages and the Europe Foods & Beverages segments and inclusion of the So Delicious Dairy Free(R) business that was attained in fourth quarter 2014. On a constant currency basis, net sales raised 13 percent in first quarter 2015 over the same period in 2014. Not taking into account the results of So Delicious, organic constant currency net sales raised 10 percent in first quarter 2015 over the same period in 2014.
Adjusted operating income for first quarter 2015 raised 17 percent to $75 million, contrast to $64 million in first quarter 2014. On a constant currency basis, adjusted operating income raised 21 percent in first quarter 2015 over the same period in 2014.
The WhiteWave Foods Company, a consumer packaged food and beverage company, manufactures, markets, distributes, and sells branded plant-based foods and beverages, salads, fruits and vegetables, coffee creamers and beverages, and dairy products and organic produce in North America and Europe.
At the end of Friday’s trade, Shares of The Gap, Inc. (NYSE:GPS), lost -1.07% to $39.61.
The Gap, revealed a partnership with Ellen DeGeneres’ new lifestyle brand, ED. The ED brand, comprising of women’s apparel, accessories & decorative home, is inspired by the iconic style, values and personality of DeGeneres. GapKids x ED is an apparel collection and social movement designed to assist all girls realize they have the power to do extraordinary things. The collection will be accessible for purchase starting August 17, 2015 through Gap.com, in all GapKids stores in the United States, and select stores in Canada, United Kingdom, China and Japan.
The Gap, Inc. operates as an apparel retail company worldwide. It offers apparel, accessories, and personal care products for men, women, and children under the Gap, Banana Republic, Old Navy, Athleta, and Intermix brand names.
Finally, Bristol-Myers Squibb Company (NYSE:BMY), ended its last trade with 2.89% gain, and closed at $66.93.
Bristol-Myers Squibb Company, declared results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial (BENEFIT) in kidney transplant patients, which demonstrated a statistically noteworthy43% relative risk reduction of death or graft loss (transplant failure) in patients receiving the Nulojix (belatacept) FDA-approved dosing regimen over those receiving a cyclosporine regimen (hazard ratio=0.57, p=0.0286). Data also showed that there was a statistically noteworthy survival benefit of 52% relative risk reduction of death or graft loss at 5 years post-transplant (hazard ratio=0.477, p=0.0045). In the long-term follow-up (years 3-7) on BENEFIT participants, the safety profile of the Nulojix regimen was similar to the cyclosporine regimen. Nulojix is the first selective T-cell costimulation blocker indicated in combination with basiliximab induction, mycophenolate mofetil (MMF) and corticosteroids for the prophylaxis of organ rejection in adult Epstein-Barr Virus (EBV) seropositive patients receiving a kidney transplant. The 7-year BENEFIT results were presented in the plenary session at the 2015 American Transplant Congress (ATC) in Philadelphia.
The BENEFIT trial is a 36-month clinical study with long-term follow-up through 84 months, with primary endpoints of composite patient and graft survival by 12 months, rate of acute rejection by 12 months, and composite measured glomerular filtration rate (GFR, a measure of renal function) <60 at month 12 or a decrease in measured GFR from month 3 to month 12. Secondary endpoints were measured at 36 months.
In the BENEFIT 7-year study follow-up, the rates of serious adverse events were similar across treatment groups (69% among patients receiving the Nulojix regimen and 76% among patients receiving the cyclosporine regimen). The incidence rates (calculated as per 100-person years) were also similar among both groups for fungal infections (6.7 and 7.6, respectively), viral infections (14.2 and 15.7, respectively) and malignancies (1.7 and 2.6, respectively). Post-transplant lymphoproliferative disease (PTLD) occurred in 2 patients in the Nulojix regimen group and 2 patients in the cyclosporine regimen group. Both PTLD cases in the group treated with the Nulojix regimen occurred before month 12.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
